VJHemOnc is committed to improving our service to you

ERIC 2020 | COVID-19 in the GAIA/CLL13 trial

VJHemOnc is committed to improving our service to you

Barbara Eichhorst

Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses how COVID-19 has impacted the GAIA/CLL13 trial (NCT02950051). Between March and April 2020, 7 patients in the clinical trial tested positive for COVID-19. Of the 7 patients, 2 died. However, in the recent resurgence of COVID-19, no patients involved in the trial have tested positive for the virus. This is the first analysis of chronic lymphocytic leukemia (CLL) patients receiving venetoclax combination therapy as a first-line treatment. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter